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Abstract 
 
Valproic acid (VPA) is a broad-spectrum antiepileptic drug that is 
now used commonly for several other neurological and psychiatric 
indications. While VPA is usually well tolerated, on rare occasions, it has 
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been associated with severe, and sometimes, fatal liver injuries. These 
complications may also arise due to acute VPA overdose.  
As a branched chain carboxylic acid, VPA is readily metabolized in 
the liver via glucuronic acid conjugation, mitochondrial β- and cytosolic 
ω-oxidation to produce multiple metabolites, and it is probably some of 
these metabolites that are involved in its toxicity. While the actual 
mechanism of VPA hepatotoxicity is still not understood, two pathways 
have been in focus: the first involves the formation of reactive 
metabolites of VPA (and their subsequent covalent binding to cellular 
proteins) and the second is the development of oxidative stress in the cell. 
We describe here a culture system based on 3D spheroid culture of 
immortal hepatocytes which can determine the toxicity of valproic acid 
(or structurally or functionally related molecules) in vitro. The spheroids 
were used to follow changes in ATP production, glucose uptake and 
adenylate kinase following treatment and can be treated repeatedly with 
VPA to determine both acutely-lethal and chronically-lethal doses. This 
system is homeostatic and has been shown to be metabolically stable over 
at least 24 days and can therefore be used to follow recovery after 
treatment. 
 
Keywords: 3D Spheroid culture; drug toxicity; valproic acid; acute lethal 
threshold; chronic lethal threshold 
 
 
Introduction  
 
When cells are grown in three dimensional (3D) environments (i.e. as 
multilayers or clusters in suspension, on scaffolds etc.) they have been shown 
to possess a number of physiological characteristics which makes them 
resemble more closely the native tissue from which they originated than the 
same cells grown in classical two dimensional (2D – i.e. as monolayers) 
conditions in culture flasks or microtitre plates.  
This may be due to the fact that cells grown in 3D cell culture are allowed 
to develop a more elaborate extracellular matrix and better intercellular 
communication [1], [2], [3], and this leads to a recovery or maintenance of in 
vivo function [4].  
For this reason, we recently investigated how long it takes cells to recover 
from trypsinisation. Our studies revealed that the hepatocyte cell line HepG2-
C3A went through some form of transition after 18 days, after which several 
key metabolic traits (growth rate, ATP levels, urea and cholesterol production) 
all stabilised[5]. A review of the literature showed that this was not a unique 
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phenomenon and there were several well-known cell lines (including the cell 
lines Caco-2, HT 29, MDCK, MCF-10A and HepG2 used to model the small 
and large intestine, kidney, breast acini and liver respectively) which all 
needed similar periods of time to fully establish themselves. We therefore 
suggested that these changes represent a ubiquitous recovery process after 
trypsinisation rather than differentiation as is often stated. This would help to 
explain why three dimensional structure has been proposed as the missing link 
which will provide in vitro models that sufficiently mimic in vivo conditions 
[6], [7] and [8]. 
In this study we have exploited the potential offered by 3D spheroid 
culture to investigate drug treatment over extended periods of time. After the 
18 days needed to recover from trypsin, 3D spheroid cultures are essentially 
homeostatically stable from 18 days to at least 42 days of culture [9]. They 
grow slowly, have a high survival percentage; their physiological capabilities 
(glycogenesis, ATP, cholesterol and urea synthesis and drug metabolism) are 
constant; and they have a stable gene expression of several key genes related 
to the main liver pathways. Furthermore, they appear to more predicitive than 
primary hepatocytes or similar cells when grown in classical 2D cultures of the 
in vivo toxicity in man, at least for a small number of drugs [10]. All in all, this 
makes 3D spheroids ideal for long term studies – for example to investigate 
drug induced liver injury (DILI).  
Valproic acid (VPA) has become one of the most widely prescribed 
anticonvulsant and mood-stabilizing drug worldwide. Despite the 
pharmacological importance and the effectiveness of VPA, its potential 
hepatotoxicity is still a major concern. The recommended VPA starting dose is 
between 750 and 1500 mg daily taken in divided doses and then dosages are 
adjusted based on response and blood level. The usual effective dose range is 
between 1000 and 2000 mg daily.  
VPA may have its beneficial neurological effects by increasing the 
concentration of the inhibitory neurotransmitter Gamma Amino Butyrate 
(GABA). VPA acts as a double edged sword causing partial creatine 
deficiency in the brain by stimulating the GABA-forming enzyme glutamate 
decarboxylase (GAD65/67); and inhibiting 2-oxoglutarate dehydrogenase (a 
rate-limiting mitochondrial Kreb’s cycle enzyme) and the GABA-catabolizing 
enzymes GABA transaminase (GABA T) and succinic semialdehyde 
dehydrogenase (SSADH)[11][12]. This becomes toxic if GABA levels are 
raised too far. 
However, treatment with VPA can also lead to liver toxicity, or more 
specifically drug-induced liver injury (DILI). This is an unresolved problem 
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which has significant clinical and economic impacts [13][14]. While the exact 
mechanisms of DILI remain largely unknown [15] there are several areas 
under investigation [16]. In the liver, the disturbance of mitochondrial function 
(including the inhibition of mitochondrial β-oxidation) leads to 
microvesicularfatty liver [17] and the impairment of oxidative phosphorylation 
and reduction of ATP synthesis [18][19][20].  
Finally, valproic acid can also cause epigenetic effects due to a histone 
deacetylase inhibitor activity (which would then stimulate gene expression in a 
more or less specific manner) [21]. 
Using the two key advantages of hepatic spheroids, namely their long term 
stability and the fact that they are homeostatic and metabolically ‘in 
equilibrium’ we describe here the effects of VPA treatment and define two 
different lethal treatment thresholds, (one for a single treatment (acute) and 
one for multiple treatments (chronic)) by measuring basic physiological 
parameters of glucose uptake, cellular ATP levels and the release of adenylate 
kinase. The results suggest that cell death by single high doses of VPA (acute) 
are different to cell death caused by multiple low doses of VPA (chronic). 
 
 
Materials and Methods 
 
Standard 2D Cell Culture Conditions 
 
The immortal human hepatocyte cell line, HepG2/C3A (ATCC CRL-
10741, third passage after receipt from ATCC, Manassas, Virginia.), were 
thawed from liquid nitrogen storage and cultured in standard tissue culture 
conditions in a customised D-MEM growth medium (87.5% D-MEM (1 g 
Glucose/L) (Gibco (Carlsbad, California) Cat. no. 31885-023); 1% Non 
Essential Amino Acids (Gibco Cat. no. 11140-035); 10% FCS (Foetal calf 
serum) (Sigma (St. Louis) Cat. no. F 7524); 0.5% Penicillin / Streptomycin 
(Gibco Cat. no. 15140-122) 1% GlutaMAX (Gibco Cat. no. 35050-038), 37⁰C, 
5% CO2 95% air). 
In order to generate cells for spheroid construction, the C3A cells were 
initially propagated using traditional 2D tissue culture. Cells were trypsinised 
(0.05% Trypsin / EDTA Cat. no.: Gibco 15400-054) for 3 minutes and sown 
out into falcon flasks/microtitre plates and cultivated at 37⁰C, 5% CO2 95% air 
in a humidified incubator.  
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To eliminate any effects of storage in liquid nitrogen or thawing, cells 
were grown for at least three passages before starting the experiments, 
exchanging the medium every two to three days. Cells were used between 
passages 4 and 15. The doubling time for C3A cells grown under these 
conditions was 76 hours.  
 
 
3D Spheroid Culture Conditions 
Preparation of Spheroids Using AggreWell™Plates 
 
The C3A cell spheroids have been prepared with use of AggreWell
TM
 400 
plates (Stemcel Technologies (Grenoble, France) Cat. no. 27845). Each 
AggreWell™ plate has 6 wells and each of these contains approximately 4,700 
microwells measuring 400 µm in diameter. These plates are used to form cell 
aggregates. Before use, the plates were washed twice with growth medium 
(customised D-MEM). In order to remove all residual air bubbles from the 
well surface the plates were prefilled with 0.5 ml of growth medium and 
centrifuged (3 min with 3,000 x g). Cells (1.2 x 10
6
) were added to each well 
and the plates were centrifuged (3 min with 100 x g) and left in the 
AggreWell
TM
 plate overnight to form spheroids. 
 
 
Spheroid Culture in ProtoTissue™ Bioreactors 
 
The spheroids were detached from the AggreWell
TM
 plates by gently 
washing the wells with prewarmed growth medium. The detached spheroids 
were collected in to a Petri dish and the quality of the spheroids checked by 
microscopy. Compact spheroids were introduced into ProtoTissue™ 
bioreactors (MC2 Biotek, (Hørsholm, Denmark) Cat. no. 010). These 
bioreactors are specially constructed to be easy to open and close and designed 
to maintain 100% humidity around the growth chamber. The spheroids 
(approximately 300 per bioreactor) were then cultivated at 37⁰C, 5% CO2 95% 
air in a humidified incubator for a minimum of 21 days, exchanging the 
medium every two to three days [22].  
The day when the cells were transferred into the bioreactor is defined as 
day 0. An estimated 90% of the medium was changed on day 1 and thereafter 
three times a week during the recoveryperiod. To achieve a stable suspension 
of spheroids, the rotation speed of the bioreactors was initially set between 21-
23 rpm and it was adjusted to compensate for the growth in size of the 
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spheroids (and reached 27-30 rpm on day 21). Speed adjustments were made 
so that inter-spheroid contact was minimised and these adjustments were made 
more frequently at the beginning of the culture than at the end. Because the 
spheroids get larger with time, the population density of the spheroids was 
regulated by opening the bioreactor and ‘splitting the population’ byremoving 
excess spheroids (this usually needed to be performed between day 11 and 14). 
Before use, the spheroid batch quality was assessed by staining for 3 min. with 
0.4% Trypan Blue (Gibco Cat. no. 15250-061). Batches showing greater than 
90% viability were accepted.  
 
 
Microscopy and Planimetry 
 
Photomicrographs were taken using an Olympus IX81 motorised 
microscope, and an Olympus DP71 camera. Images were transferred to the 
Olympus AnalySiS
®
Docu program (Soft Imaging System) and the ‘shadow’ 
area of spheroids measured using the ‘Fitted Polygon Area’ function which 
calculates the planar surface of the spheroids in µm². 
 
 
Drug Treatment 
 
Valproic acid (VPA) was purchased from Sigma (Cat no. P4543). Stock 
solutions were prepared just before use by dissolving the compound in either 
growth medium or DMSO (Sigma Cat. no. D2650) and diluted into growth 
media. A control media was prepared which contained the same concentration 
of DMSO vehicle without any compound. The maximum final DMSO 
concentration was 0.01%. 
Three hundred 21-day old spheroids (corresponding to approximately 25 
million cells or 3.5 mg protein) were gently pipetted (using a cut-tip) into each 
10ml bioreactor before treatment to provide ample material for analysis. To 
initiate drug treatment, the bioreactor rotation was stopped for 30 s to allow 
the spheroids to settle to the bottom of the bioreactor. Ninety percent of the 
media volume was exchanged with media containing the compound at 
concentrations which gave the final treatment concentrations given in the 
figures. Experiments to determine the LD50 were carried out initially using a 
broad range of drug concentrations (e.g. varying by a factor of ten) followed 
by two experiments using a narrow concentration range (varying typically by a 
factor of four).  
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The data from the broad range of VPA concentrations were used to 
identify the final narrow range used, and so these data are not presented. Each 
narrow range experiment was carried out in duplicate and ATP was measured 
in technical triplicates for each sample. Media was exchanged at 48, 96, 168, 
216 and 264 h after the start of the experiment. 
 
 
ATP Assay 
 
Cell viability was measured based on their ability to produce ATP [23]. 
Samples of the hepatocytes grown as spheroids were collected (usually 2 - 6 
spheroids per assay point depending on the size of the spheroids) at 
appropriate times and transferred to white opaque microtitre plates (Nunc, 
(Roskilde, Denmark) Cat. no. 165306), the volume of growth medium was 
adjusted to 100 µl.  
The cells were then lysed with 100 µl of lysis buffer (CellTiter-Glo 
luminescent cell viability assay, Promega (Fitchburg, WI) Cat. no. G7571) and 
shaken in the dark for 20 min. before the luminescence was measured in a 
FluoStar OPTIMA (BMG Labtech, Ortenberg, Germany) using the following 
parameters: one kinetic window, 10 measurement cycles with 0.3 s of 
measurements interval time, 2 s delay per measurement, additional 0.5 s delay 
per position change, (repeated twice for each measured plate). Replicates were 
performed as described under ‘Drug Treatment’.  
The data was normalised with reference to a standard curve for ATP and 
to the untreated control. 
 
 
Adenylate Kinase Assay for Cell Viability 
 
Adenylate kinase was measured using the bioluminescent cytotoxicity 
assay kit (LonzaToxilight assay kit, cat. no. LT07-117). Spent media from 
spheroid cultures were collected in triplicate in connection with refreshing the 
growth media (typically at 48 h intervals), diluted with five volumes of 
adenlyate kinase detection reagent, allowed to incubate for five minutes and 
then read the bioluminescence in a Fluostar Omega® (BMG Labtech) using 1 
second measurement interval time per each measured well. A standard curve 
was prepared in the same way for each assay plate using a cell standard (4.29 
million C3A cells per mL lysed in lysis buffer). Gain was adjusted based on 
the highest standard curve values. 
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Protein Determination 
 
In order to correlate the shadow area of the spheroid to its protein content, 
the latter was determined using the fluorescence based ProStain Protein 
Qantification Kit (Active Motif, Inc (La Hulpe, Belgium) Cat. no. 15001) 
according to the manufacturer’s instructions. All data was expressed as a 
function of the amount of protein present. 
 
 
Glucose Determination 
 
Samples for glucose determination were collected from every culture at: 0, 
4, 24, 48, 52, 72, 96, 100, 168, 174, 192, 216, 222, 240, 264 and 270 h and 
frozen until needed. Glucose was measured using a ‘Onetouch Vita glucose 
meter’ and test strips, (MediqDanmark, Cat No. 6407078 Cat. No. 6407079 
respectively). 
The instrument was calibrated using a 1 mg/ml D-glucose standard 
solution, (Sigma-Aldrich Cat. No. G3285-5ML) and Onetouch Vita control 
solution (MediqDanmark Cat.No. 64-07-081). Standards and samples were 
warmed to room temperature and shaken on a rotary shaker at 450rpm for 1 h. 
For each measurement a test strip was inserted into the instrument and 2-3 µl 
of each sample were spotted onto it. The glucose concentration is read 
immediately.  
 
 
Results 
 
This study was set up to investigate the effects of repeatedly treating 
hepatocyte spheroids grown in rotating bioreactors with various doses of VPA, 
to mimic the repeated treatment of patients in vivo and thus to investigate the 
molecular changes occurring during the development of drug-induced liver 
injury (DILI).  
When spheroids are formed using Aggrewell™ plates and grown in the 
bioreactors (figure 1) using the procedures described here, they are quite 
uniform in size (± 21% [10]). A few spheroids are shown in figure 2 to 
illustrate this (a lower power image of many spheroids can be seen in [10]). 
They can be expected to respond more uniformly than spheroids of different 
sizes (for example in large spheroids the outer cells might metabolise the drug 
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and thus inner cells would be shielded from the full drug concentration, 
whereas cells in a small spheroid will all receive the full dose). 
 
 
Figure 1. A bioreactor used in this study. Spheroids are cultivated in the 10ml chamber in 
front of the white membrane and the air in the chamber behind the membrane is humidified. 
The spheroid cultivation chamber can be opened to give a petri-dish like access to the 
spheroids. The two round plugs measure 1.5 cm and give access to either the growth 
chamber or to refill the humidification reservoir. The ‘tall’ white plug is removed when 
changing the media.  
 
Figure 2. 21 day-old spheroids. Photograph of a small number of 21 day-old spheroids to 
illustrate their uniformity. Note that there is very little cellular contamination in the media. 
Scale bar = 1mm. 
Stephen J. Fey and Krzysztof Wrzesinski 150 
 
 
 
 
 
 
Determination of Acute Lethal and Chronic Lethal Dose … 151 
 
Figure 3. Relationship between spheroid shadow area, protein content and number of cells. 
The spheroid shadow area was measured in four separate experiments and the data 
combined, averaged and smoothed. A) Averaged spheroid shadow area (on average 180 
spheroids were measured per data point). B) the averaged protein content per mm2 of the 
shadow area of the spheroid. Error bars in A) and B) represent the standard deviation of the 
unsmoothed data. C) Calculated protein content of a spheroid depending on it’s age; D) 
calculated number of cells in a spheroid depending on it’s age. The data have been 
smoothed so that the graphs can be used as look up tables for the actual experiments. 
The relationship between the size of a spheroid (it’s shadow area), their 
protein content and the calculated number of cells contains is shown in figure 
3 for spheroids from their day of formation (day 0) to day 42.  
In order to determine the acute and chronic lethal concentrations at which 
valproic acid kills human C3A spheroids, twenty one day old spheroids were 
treated with different concentrations of valproic acid. The spheroids were 
repeatedly treated with VPA by exchanging ninety percent of the growth 
media (containing the appropriate VPA concentration) after 48, 96, 168, 216 
and 264 h (2, 4, 7, 9 and 11 days). Only ninety percent of the media was 
exchanged to reduce the risk that the spheroids agglomerated.  
Measurements of cellular ATP levels have been suggested to be one of the 
best indicators of cellular viability [23]. A small number of spheroids (so as 
not to substantially affect the total number in the bioreactor) were collected 
from each culture during each media refreshment, in order to determine ATP 
levels. The actual number collected depended on the size of the spheroids and 
was typically between six and two depending on the age of the culture. All 
data have been normalised with respect to the amount of ATP present in the 
control, mock treated culture at the same age. 
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The results (figure 4) show that a dose of 20 milligram VPA per milligram 
total cellular protein (20 mg VPA/mg TCP) was sufficient to reduce cellular 
ATP levels to lower than 30% after 24 hours and lower than 11% after 48 
hours. The second treatment killed the remaining few cells.  
Treatment of the spheroids with the first dose of 4 mg VPA/mg TCP 
resulted in a fall of ATP levels to about 75% of the control levels (figure 4). 
After the second, fourth and fifth doses cells appeared to be able to recover 
their ATP levels to normal. However there was a trend that, at each subsequent 
dose, the ATP levels are supressed lower and lower and by extrapolation, one 
could anticipate that if treatment was repeated a few times more that the cells 
would die (after the sixth treatment the ATP levels were down to that seen 
with one treatment of 20 mg VPA/mg TCP.  
Lower doses (0.8 and 0.16 mg VPA/mg TCP) perturbed the ATP levels 
but each time the ATP levels recovered to essentially the same level as seen in 
the untreated controls. ATP levels above that seen in the controls were 
frequently measured. In order to investigate the system further, we 
investigated glucose consumption of the cultures because VPA has been 
shown to have a profound effect on glucose metabolism [24]. Fresh growth 
media contains 1 mg/mL glucose (ca. 5.5 mM). The glucose levels of the 
cultures were measured each time the media was changed (at 48, 96, 168, 216 
and 264 h) and again 4 or 6 h after the media change. Thus glucose levels were 
measured at 0, 4, 24, 48, 52, 72, 96, 100, 168, 174, 192, 216, 222, 240, 264 
and 270 h for every culture. Figure 5 reflects the actual amount of glucose in 
the growth media, and shows for example typically that most of the glucose in 
the media had be consumed 24 h after its refreshment even at moderate VPA 
doses. Interpreting the data becomes easier if one views selected 
measurements. Figure 6A shows only the glucose measurements made 4 or 6 h 
after refreshing the growth media and figure 6B shows the glucose 
concentrations in the spent media before refreshment. These selected data 
show that there is a clear correlation between the VPA dose and ability to 
remove glucose from the media.  
At high VPA doses the spheroids rapidly lose the ability to import glucose 
while spheroids treated with low doses and the mock-treated control became 
increasing proficient at doing so. figure 3Exactly the same interpretation can 
be reached by viewing the glucose concentrations in the spent media (figure 
6B). Spheroid cultures treated with the highest VPA (20 mg VPA/mg TCP) 
managed to remove about 70% of the glucose from the media in the first 48 
hrs (long dashes in figure 6B). Thereafter they showed no ability to remove 
glucose and were essentially dead. Again spheroids treated with the 4 mg 
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VPA/mg TCP dose initially can cope with the treatment but at later stages 
(after 168 hrs) have almost lost the ability to import glucose (medium length 
dashed line in figure 6B). 
 
 
Figure 4. ATP content of cells in VPA treated spheroids. The spheroids were treated with 0 
(____ solid line), 0.16 (……. Dotted line), 0.8 (--- short dash), 4 (- - - medium dash) and 20 (__ 
__ __ long dash) mg VPA/mg total cellular protein (TCP) at the timepoints indicated by the 
hollow arrows on the abscissa. The data has then been normalised to the mock-treated 
control at the same timepoint. Error bars (only positive bar shown for clarity) show the 
standard deviation calculated from the average of triplicate technical replicates for two 
independent biological replicates. 
The final question we investigated was whether the changes in cell 
reactivity was related to apoptosis or necrosis [25][26]. In apoptosis, cell death 
is an ATP-driven, carefully programmed process whereas in necrosis, cell 
death is a result of a cellular trauma (e.g. infection or poisoning) that the cell 
cannot cope with. Necrosis is an ATP independent event which results in the 
massive release of cellular contents, including the enzyme adenylate kinase 
and this results in inflammation of the surrounding cells). Measurements of 
adenylate kinase release reveal an interesting aspect to what is happening in 
the cultures (figure 7). Treatment with the high dose of VPA (20 mg VPA/mg 
TCP) caused a clear release of adenylate kinase, peaking at 48hrs.  
Thereafter the amount falls as there are fewer living cells left which can 
release the enzyme. No other VPA dose gave rise to a similar reaction pattern. 
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When compared to the mock treated control, all three of the other VPA doses 
appear to repress adenylate kinase release in a dose dependent manner, 
especially at later timepoints.  
Since low ATP levels do not lead to mitochondrial membrane 
depolarisation, the spheroid cells are probably dying via necrosis. This is 
consistent with breach of the plasma membrane and release of adenylate 
kinase at the high doses of VPA (20 mg VPA/mg TCP) [29]. 
However, the moderate doses of VPA (i.e. 4 mg VPA/mg TCP) also lead 
towards a slow ATP depletion, and since apoptosis is ATP dependent then 
these moderate doses would also be expected to be driving the hepatocytes 
also towards an ATP-independent necrotic death despite the absence of 
adenylate kinase release. Thus it appears that there could be differences in the 
necrotic pathways. This needs to be explored further, for example by 
measuring cytochrome c release, glutathione, Bcl-2 and caspase 3 activation 
during these processes [30][31] and [32]. 
 
 
Figure 5. Glucose clearance from the media. The amount of glucose remaining in the 
growth media was measured during the VPA treatment. All other details as in figure 4, 
except that the data were not normalised to the control. 
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Figure 6. Glucose clearance from the media. Subsets of data shown in figure 5. Glucose 
levels remaining in the growth media A) four or six hours after refreshing the media and B) 
in the spent media immediately before refreshment.  
Apoptosis is an energy dependent process and is usually associated with 
mitochondrial membrane depolarisation and release of cytochrome C [27]and 
[28].  
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Discussion 
 
The goal of this study was to investigate the suitability of 3D spheroids for 
long term drug treatment using VPA as the test compound, with the long term 
aim of using the system to investigate drug-induced liver injury. Our approach 
was to treat mature 3D spheroids with different concentrations of VPA 
repeatedly at two or three day intervals. Cell viability and cytotoxicity was 
then measured by following the total cellular ATP content, the glucose 
concentration of the media and the release of adenylate kinase. 
 
 
Figure 7. Adenylate kinase levels in the media. The amount of adenylate kinase released 
into the growth media during the VPA treatment. All other details as in figure 4.  
The data presented here showed that spheroids treated with high levels of 
VPA (20 mg VPA/mg TCP) rapidly lost their ability to synthesise ATP, 
import glucose and they released large amounts of adenylate kinase. Moderate 
levels of VPA (4 mg VPA/mg TCP) caused a slow loss in the ability to 
synthesise ATP (over a 10 day period) and a corresponding slow loss in the 
ability to import glucose. Low levels of VPA (0.8 and 0.16 mg VPA/mg TCP) 
induced an initial increase in ATP levels, despite a lowered glucose 
consumption. Both moderate and low levels of VPA treatment reduced the 
amount of adenylate kinase released to below control levels. This is 
presumably because the number of cells in the spheroids is increasing. From 
this data it is clear that spheroids treated with the 4 mg VPA/mg TCP dose 
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initially can cope with the treatment but at later stages (after 168 h) are losing 
the ability to import glucose.  
 
 
Molecular Basis for VPA Toxicity 
 
Measurement of glucose levels in the 3D cultures were quite revealing 
because they showed that mock treated cultures cleared the glucose from the 
media very quickly, probably in about 12 hours and certainly by 24 h. 
Presumably, the cells are importing the glucose and synthesising glycogen 
(glycogen granules have been described in 3D spheroid cultured cells [5]). At 
high oxygen and glucose levels the C3A cells are probably functioning 
‘inefficiently’ and exhibit the Crabtree effect and reduce Kreb’s cycle activity 
[33][34]. When the glucose levels in the media fall, the cells will activate the 
glycolytic pathway and the theKreb’s cycle so that they can hydrolyse 
glycogen and metabolise glucose efficiently in order to ‘survive’ until the next 
media change.  
It has been shown that VPA causes the inhibition of glycogen synthase 
kinase-3 (GSK-3) [25], [35] (in a manner analogous to lithium, another mood 
controlling compound [36]). This would be expected to lead to an increase in 
glycogen synthesis which in turn would to cause an increase in glucose uptake 
from the media. This effect was never seen in the studies presented here even 
at the lowest VPA doses investigated and therefore if VPA is acting through 
GSK-3 must be occurring via one of GSK-3’s other roles. Another possibility 
is via a signalling pathway [36].  
GSK-3 is a part of the canonical β-catenin/Wnt pathway, which signals the 
cell to divide and proliferate [37] and thererfore inhibition of GSK-3 would be 
expected to slow these cellular activities. However, in spheroids, cells are 
growing very slowly and therefore GSK-3’s inhibition would be expected also 
to have a minimal effect and so once again, VPA treatment is probably not 
operating via this pathway.  
A more probable explanation is that VPA is a simple fatty acid and as 
such can be a substrate for the fatty acid b-oxidation pathway. This occurs 
primarily in the mitochondria and is known to result in a cumulative inhibitory 
effect on long-chain fatty acid b-oxidation [20] [38][39]. Simultaneous 
inhibition of the mitochondrial pyruvate uptake will impair the pyruvate-
driven oxidative phosphorylation and together with the inhibition of 2-
oxoglutarate dehydrogenase reduce ATP synthesis [11], [12], [18], [19], [20] 
and [40]. This is potentially the primal cause of both the observed reduction of 
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glucose uptake and the fall in cellular ATP levels (at moderate or high VPA 
doses). 
 
 
Acute and Chronic Lethal Thresholds 
 
The treatment of spheroids revealed that there were two different ‘lethal 
thresholds’. At high VPA doses (20 mg VPA/mg TCP), the cells were killed 
essentially immediately by one dose and we defined this as the ‘acute lethal 
threshold’. Above this dose a single dose is sufficient to kill the cells whereas 
below this dose, the single dose is not sufficient to kill. 
A VPA dose five times lower than the acute lethal dose resulted in a fall 
of the ATP level to 75% of the control. At each subsequent dose, the ATP 
levels were supressed lower and lower and the cells would be expected to die 
if treatment was repeated a few times more. Exactly analogous results were 
obtained measuring glucose clearance from the media: the spheroids were 
increasingly inept following each successive treatment. Thus one can infer that 
the chronic lethal threshold dose will be about 4 mg VPA/mg TCP. Based on 
the ATP data, above this dose (but below 20 mg VPA/mg TCP) it would be 
anticipated that cultures will die if repeatedly treated with VPA, while below 
this dose they will not die. 
Lower doses (0.8 and 0.16 mg VPA/mg TCP) perturbed the ATP levels 
but each time the ATP levels recovered to essentially the same level as seen in 
the untreated controls. ATP levels above that seen in the controls were 
frequently measured: this is interpreted to indicate additional cellular activity 
to repair VPA-induced cellular damage (e.g. the replacement of VPA 
metabolite-cellular protein covalent adducts [41] or the repair of other damage 
done to the cell and its membranes [42]. Extrapolation of these data would 
suggest that these lower doses would be unable to kill the C3A spheroids 
irrespective of how often the cells were treated. 
From the data that we obtained, it appears that the acute lethal dose and a 
chronic lethal dose kill the cells by different mechanisms: in the acute 
situation, there is a sudden release of adenylate kinase; whereas in the chronic 
situation (at a VPA dose only 5 times lower), there is an apparent ‘repression’ 
of adenylate kinase release. The explanation of this is not clear. One possible 
explanation is that if cells are releasing adenlyate kinase immediately after 
chronic VPA treatment, then because the enzyme has a short half-life in 
solution (ca. 6 h) it cannot be detected when the assay is carried out 48hrs after 
treatment. Another explanation could be that the VPA treatment is merely 
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paralysing cellular activity, including adenylate kinase release, and not 
resulting in cell death.  
The lower than control adenylate kinase levels (‘repression’) could then be 
a reflection of the fact that the control cells are growing whereas the treated 
cells are presumably not.  
 
 
Modelling the Treatment Regimen 
 
Currently, the FDA official recommendation for the initiation of VPA 
treatment using sodium valproate injection is to start therapy at 10 to 15 
mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve 
optimal clinical response [43]. Since the liver is almost the exclusive site for 
VPA metabolism, it could be expected that the apparent chronic ‘cellular 
paralysis’ (failing glucose import and falling ATP levels) induced by low 
levels of VPA treatment, might slow the metabolism and removal of VPA. 
Subsequent doses would then result in a positive feedback situation increasing 
the ‘effective dose’ because the liver’s capacity to respond is successively 
impaired. This situation therefore underlines the importance of slowly 
increasing the dose given to the patient.  
 
 
Dose Frequency 
 
In the model described here we have used a single constant dose given 
each 48 or 72hrs. Since the half-life of VPA is 10 – 20 h [44] one could argue 
that the VPA is given too infrequently. However, in vitro the VPA metabolites 
are not removed as they are in vivo by the kidneys and therefore the biological 
half life in vitro would be expected to be longer. 48hr treatment intervals were 
used to minimise disturbances to the spheroids in the bioreactor cultures. If 
VPA had been given more frequently, then one would expect that the chronic 
threshold value identified would be lower. The ideal in vitro situation would 
probably be a continuous perfusion supply and this would be expected to 
reveal the lowest threshold values. However this would not mimic the 
intermittent treatment effect when compounds are administered to patients. 
The spheroid system described here, because of its stability (extending over 
weeks) and the relative ease with which small samples can be removed 
without perturbing the system (i.e. changing the drug cell number ratio) could 
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be used to provide in vitro data to match at least part of the theoretical 
simulations of mathematical models [45].  
 
 
Conclusion 
 
The 3D spheroid model, because of its homeostatic ability to recover 
following treatment and it stability over relatively long periods of time, offers 
an excellent model for studying long term effects of compounds like VPA on 
liver cells and for studying the effects of repeated insult leading for example to 
the development of drug-induced liver injury. 
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